vs
Side-by-side financial comparison of Axos Financial, Inc. (AX) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $392.2M, roughly 2.0× Axos Financial, Inc.). Axos Financial, Inc. runs the higher net margin — 31.8% vs 13.0%, a 18.8% gap on every dollar of revenue. Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 16.1%).
Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
AX vs PODD — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $392.2M | $783.7M |
| Net Profit | $124.7M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | 31.8% | 13.0% |
| Revenue YoY | — | 31.2% |
| Net Profit YoY | 18.5% | 0.9% |
| EPS (diluted) | $2.15 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $392.2M | — | ||
| Q4 25 | $385.1M | $783.7M | ||
| Q3 25 | $323.4M | $706.3M | ||
| Q2 25 | $321.4M | $649.1M | ||
| Q1 25 | $308.8M | $569.0M | ||
| Q4 24 | $307.9M | $597.5M | ||
| Q3 24 | $320.7M | $543.9M | ||
| Q2 24 | $290.9M | $488.5M |
| Q1 26 | $124.7M | — | ||
| Q4 25 | $128.4M | $101.6M | ||
| Q3 25 | $112.4M | $87.6M | ||
| Q2 25 | $110.7M | $22.5M | ||
| Q1 25 | $105.2M | $35.4M | ||
| Q4 24 | $104.7M | $100.7M | ||
| Q3 24 | $112.3M | $77.5M | ||
| Q2 24 | $104.9M | $188.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% |
| Q1 26 | — | — | ||
| Q4 25 | 45.6% | 18.7% | ||
| Q3 25 | 46.3% | 16.7% | ||
| Q2 25 | 48.5% | 18.7% | ||
| Q1 25 | 47.9% | 15.6% | ||
| Q4 24 | 48.8% | 18.3% | ||
| Q3 24 | 49.6% | 16.2% | ||
| Q2 24 | 49.6% | 11.2% |
| Q1 26 | 31.8% | — | ||
| Q4 25 | 33.3% | 13.0% | ||
| Q3 25 | 34.7% | 12.4% | ||
| Q2 25 | 34.4% | 3.5% | ||
| Q1 25 | 34.1% | 6.2% | ||
| Q4 24 | 34.0% | 16.9% | ||
| Q3 24 | 35.0% | 14.2% | ||
| Q2 24 | 36.0% | 38.6% |
| Q1 26 | $2.15 | — | ||
| Q4 25 | $2.22 | $1.42 | ||
| Q3 25 | $1.94 | $1.24 | ||
| Q2 25 | $1.89 | $0.32 | ||
| Q1 25 | $1.81 | $0.50 | ||
| Q4 24 | $1.80 | $1.38 | ||
| Q3 24 | $1.93 | $1.08 | ||
| Q2 24 | $1.75 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $3.1B | $1.5B |
| Total Assets | $29.2B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.0B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | $312.7M | $939.0M | ||
| Q1 25 | $377.4M | $1.6B | ||
| Q4 24 | $358.7M | $1.3B | ||
| Q3 24 | $313.5M | $1.4B | ||
| Q2 24 | $325.7M | $1.4B |
| Q1 26 | $3.1B | — | ||
| Q4 25 | $2.9B | $1.5B | ||
| Q3 25 | $2.8B | $1.4B | ||
| Q2 25 | $2.7B | $1.5B | ||
| Q1 25 | $2.6B | $1.3B | ||
| Q4 24 | $2.5B | $1.2B | ||
| Q3 24 | $2.4B | $1.1B | ||
| Q2 24 | $2.3B | $998.4M |
| Q1 26 | $29.2B | — | ||
| Q4 25 | $28.2B | $3.2B | ||
| Q3 25 | $27.4B | $3.0B | ||
| Q2 25 | $24.8B | $3.5B | ||
| Q1 25 | $24.0B | $3.5B | ||
| Q4 24 | $23.7B | $3.1B | ||
| Q3 24 | $23.6B | $3.0B | ||
| Q2 24 | $22.9B | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | 0.12× | 0.64× | ||
| Q1 25 | 0.14× | 1.21× | ||
| Q4 24 | 0.14× | 1.07× | ||
| Q3 24 | 0.13× | 1.21× | ||
| Q2 24 | 0.14× | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | — | $48.2M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | — | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | — | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $183.3M | ||
| Q3 25 | $118.4M | $125.7M | ||
| Q2 25 | $490.3M | $196.5M | ||
| Q1 25 | $73.7M | $63.8M | ||
| Q4 24 | $162.5M | $147.7M | ||
| Q3 24 | $70.8M | $98.5M | ||
| Q2 24 | $305.5M | $96.5M |
| Q1 26 | — | — | ||
| Q4 25 | $85.4M | $48.2M | ||
| Q3 25 | $109.3M | $100.1M | ||
| Q2 25 | $436.1M | $177.9M | ||
| Q1 25 | $65.1M | $51.5M | ||
| Q4 24 | $156.4M | $94.1M | ||
| Q3 24 | $53.0M | $71.8M | ||
| Q2 24 | $269.5M | $74.0M |
| Q1 26 | — | — | ||
| Q4 25 | 22.2% | 6.2% | ||
| Q3 25 | 33.8% | 14.2% | ||
| Q2 25 | 135.7% | 27.4% | ||
| Q1 25 | 21.1% | 9.1% | ||
| Q4 24 | 50.8% | 15.7% | ||
| Q3 24 | 16.5% | 13.2% | ||
| Q2 24 | 92.6% | 15.1% |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 17.2% | ||
| Q3 25 | 2.8% | 3.6% | ||
| Q2 25 | 16.9% | 2.9% | ||
| Q1 25 | 2.8% | 2.2% | ||
| Q4 24 | 2.0% | 9.0% | ||
| Q3 24 | 5.5% | 4.9% | ||
| Q2 24 | 12.4% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.81× | 1.80× | ||
| Q3 25 | 1.05× | 1.43× | ||
| Q2 25 | 4.43× | 8.73× | ||
| Q1 25 | 0.70× | 1.80× | ||
| Q4 24 | 1.55× | 1.47× | ||
| Q3 24 | 0.63× | 1.27× | ||
| Q2 24 | 2.91× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
